leisure time -WSS

leisure time

author：hotspot 2025-09-29 21:25:36 - browse：773

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Why health workers in Gaza are injured or die at high rates

Wikipedia

WSS

Will Ozempic

Scientific mystery highlights the blind spots in genomics databases

CEOs share strategies for surviving biotech slump

Study: Black kids more likely to die after surgery than white kids

Florida Supreme Court upholds state's abortion ban

Beam Therapeutics to lay off 20% of its staff, re

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

How one medical school became remarkably diverse

Impact of Dobbs ruling felt at reproductive medicine meeting

Virginia high school admissions case could be legal follow

First Opinion Podcast: Long Covid needs a new approach

United colonoscopy coverage change 'may cost lives,' doctors say

Pharmacists can make shortage drugs, but at what cost?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Pancreatic cancer is often deadly, but new discoveries are raising hope

Novavax promises a turnaround & Lilly roils the obesity market

Insurer loopholes limit power of law against surprise medical bills

focus

Impact of Dobbs ruling felt at reproductive medicine meeting

Researchers explore possible ties between long Covid, menopause

Oral obesity drug from Viking Therapeutics hits key early target

Senate committee scrutinizes Medicare Advantage brokers

CEOs share strategies for surviving biotech slump

Republican states more likely to report Covid vaccine side effects

hotspot

Wikipedia

knowledge

leisure time